WallStSmart

Elevai Labs, Inc. Common Stock (ELAB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevai Labs, Inc. Common Stock generates 248% more annual revenue ($2.58M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ELAB earns a higher WallStSmart Score of 30/100 (F).

ELAB

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 2/9Altman Z: -2.92

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELAB1 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ELAB4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.20M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ELAB

The strongest argument for ELAB centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ELAB

The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ELAB is growing revenue faster at -45.8% — sustainability is the question.

ELAB generates stronger free cash flow (-2M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ELAB scores higher overall (30/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevai Labs, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Elevai Labs, Inc. (Ticker: ELAB) is an innovative technology firm at the forefront of artificial intelligence and machine learning, primarily catering to the healthcare and finance sectors. By leveraging sophisticated data analytics, the company empowers organizations to extract actionable insights from intricate datasets, thus enhancing operational efficiencies and supporting strategic decision-making. Positioned strategically within a dynamic technology landscape, Elevai Labs is well-prepared to harness emerging market trends for growth, underscoring its commitment to advancing AI technologies and solidifying its role as a significant player with strong potential for sustainable development and competitive advantage.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?